Genes involved in systemic and arterial bed dependent atherosclerosis - tampere vascular study

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Levula, Mari ^a   Oksala, Niku ^a   Airla, Nina ^a   Zeitlin, Rainer ^a   Salenius, Juha Pekka ^a   Järvinen, Otso ^a   Venermo, Maarit ^a   Partio, Teemu ^a   Saarinen, Jukka ^a   Somppi, Taija ^a   Suominen, VeliPekka ^a   Virkkunen, Jyrki ^a   Hautalahti, Juha ^a   Laaksonen, Reijo ^a   Kähönen, Mika ^b   Mennander, Ari ^a   Kytömäki, Leena ^c   Soini, Juhani T ^c   Parkkinen, Jyrki ^a   Pelto Huikko, Markku ^b   Lehtimäki, Terho ^a   more..

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROADHERIN; GLYCOPROTEIN; LACTOFERRIN; UNCLASSIFIED DRUG;

AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID PLAQUE; CLINICAL ARTICLE; DOWN REGULATION; FEMORAL ARTERY; FEMORAL PLAQUE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; HUMAN; HUMAN TISSUE; MAMMARY ARTERY; PATHOGENESIS; UPREGULATION; AGED; ANTIBODY SPECIFICITY; ARTERY; CASE CONTROL STUDY; FEMALE; FINLAND; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; ARTERIES; CASE-CONTROL STUDIES; FEMALE; FINLAND; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MALE; ORGAN SPECIFICITY; PLAQUE, ATHEROSCLEROTIC;

EID: 84859638571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033787     Document Type: Article

References (81)

1. Tyson KL, Weissberg PL, Shanahan CM, (2002) Heterogeneity of gene expression in human atheroma unmasked using cDNA representational difference analysis. Physiol Genomics 9: 121-130.
2. Tuomisto TT, Korkeela A, Rutanen J, Viita H, Brasen JH, et al. (2003) Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler Thromb Vasc Biol 23: 2235-2240.
3. Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, et al. (2004) Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 24: 1922-1927.
4. Randi AM, Biguzzi E, Falciani F, Merlini P, Blakemore S, et al. (2003) Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis. J Thromb Haemost 1: 829-835.
5. King JY, Ferrara R, Tabibiazar R, Spin JM, Chen MM, et al. (2005) Pathway analysis of coronary atherosclerosis. Physiol Genomics 23: 103-118.
6. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, et al. (1995) A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15: 1512-1531.
7. Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, et al. (2009) ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Ann Med 41: 279-290.
8. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
9. Smyth G, eds. (2005) Limma: Linear Models For Microarray Data. Springer, New York.
10. Shi SR, Key ME, Kalra KL, (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748.
11. Raffetto JD, Khalil RA, (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75: 346-359.
12. Greenow K, Pearce NJ, Ramji DP, (2005) The key role of apolipoprotein E in atherosclerosis. J Mol Med 83: 329-342.
13. Singh M, Ananthula S, Milhorn DM, Krishnaswamy G, Singh K, (2007) Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci 12: 214-221.
14. Cagnin S, Biscuola M, Patuzzo C, Trabetti E, Pasquali A, et al. (2009) Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries. BMC Genomics 10: 13.
15. Baker EN, Baker HM, (2005) Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 62: 2531-2539.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
17. Chu CC, Paul WE, (1997) Fig1, an interleukin 4-induced mouse B cell gene isolated by cDNA representational difference analysis. Proc Natl Acad Sci U S A 94: 2507-2512.
18. Carbonnelle-Puscian A, Copie-Bergman C, Baia M, Martin-Garcia N, Allory Y, et al. (2009) The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia 23: 952-960.
19. Marquet J, Lasoudris F, Cousin C, Puiffe ML, Martin-Garcia N, et al. Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes. Eur J Immunol 40: 2557-2568.
20. Maric M, Arunachalam B, Phan UT, Dong C, Garrett WS, et al. (2001) Defective antigen processing in GILT-free mice. Science 294: 1361-1365.
21. Barjaktarevic I, Rahman A, Radoja S, Bogunovic B, Vollmer A, et al. (2006) Inhibitory role of IFN-gamma-inducible lysosomal thiol reductase in T cell activation. J Immunol 177: 4369-4375.
22. Zhou X, (2003) CD4+ T cells in atherosclerosis. Biomed Pharmacother 57: 287-291.
23. Galkina E, Ley K, (2009) Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27: 165-197.
24. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, et al. (1992) Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883-887.
25. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, et al. (2009) Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120: 417-426.
26. Brandtzaeg P, Johansen FE, (2005) Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206: 32-63.
27. Hagg DA, Olson FJ, Kjelldahl J, Jernas M, Thelle DS, et al. (2008) Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis.
28. Reape TJ, Rayner K, Manning CD, Gee AN, Barnette MS, et al. (1999) Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. Am J Pathol 154: 365-374.
29. Moratz C, Harrison K, Kehrl JH, (2004) Regulation of chemokine-induced lymphocyte migration by RGS proteins. Methods Enzymol 389: 15-32.
30. Pellieux C, Desgeorges A, Pigeon CH, Chambaz C, Yin H, et al. (2003) Cap G, a gelsolin family protein modulating protective effects of unidirectional shear stress. J Biol Chem 278: 29136-29144.
31. Kingsbury GA, Feeney LA, Nong Y, Calandra SA, Murphy CJ, et al. (2001) Cloning, expression, and function of BLAME, a novel member of the CD2 family. J Immunol 166: 5675-5680.
32. Lim WC, Chow VT, (2006) Gene expression profiles of U937 human macrophages exposed to Chlamydophila pneumoniae and/or low density lipoprotein in five study models using differential display and real-time RT-PCR. Biochimie 88: 367-377.
33. Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, et al. (2001) Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 276: 23456-23463.
34. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, et al. (2005) Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732: 96-102.
35. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, et al. (2008) Lactoferrin structure and functions. Adv Exp Med Biol 606: 163-194.
36. Puddu P, Valenti P, Gessani S, (2009) Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie 91: 11-18.
37. Vengen IT, Dale AC, Wiseth R, Midthjell K, Videm V, Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: Long-term follow-up of the HUNT 1 study. Atherosclerosis.
38. Sahu BS, Sonawane PJ, Mahapatra NR, Chromogranin A: a novel susceptibility gene for essential hypertension. Cell Mol Life Sci 67: 861-874.
39. Ferrero E, Magni E, Curnis F, Villa A, Ferrero ME, et al. (2002) Regulation of endothelial cell shape and barrier function by chromogranin A. Ann N Y Acad Sci 971: 355-358.
40. Jansson AM, Rosjo H, Omland T, Karlsson T, Hartford M, et al. (2009) Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30: 25-32.
41. Mizuno M, Fujisawa R, Kuboki Y, (1996) Bone chondroadherin promotes attachment of osteoblastic cells to solid-state substrates and shows affinity to collagen. Calcif Tissue Int 59: 163-167.
42. Camper L, Heinegard D, Lundgren-Akerlund E, (1997) Integrin alpha2beta1 is a receptor for the cartilage matrix protein chondroadherin. J Cell Biol 138: 1159-1167.
43. Sjoberg AP, Manderson GA, Morgelin M, Day AJ, Heinegard D, et al. (2009) Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 46: 830-839.
44. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A, (1999) The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 93: 3583-3586.
45. Grenache DG, Coleman T, Semenkovich CF, Santoro SA, Zutter MM, (2003) Alpha2beta1 integrin and development of atherosclerosis in a mouse model: assessment of risk. Arterioscler Thromb Vasc Biol 23: 2104-2109.
46. Haskard DO, Boyle JJ, Mason JC, (2008) The role of complement in atherosclerosis. Curr Opin Lipidol 19: 478-482.
47. Li F, Tian F, Wang L, Williamson IK, Sharifi BG, et al. Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-{gamma}/JAK/STAT1 signaling is critical for the expression of PTN in macrophages. Faseb J 24: 810-822.
48. Sharifi BG, Zeng Z, Wang L, Song L, Chen H, et al. (2006) Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol 26: 1273-1280.
49. Hansson GK, Robertson AK, Soderberg-Naucler C, (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1: 297-329.
50. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, et al. (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 93: 14002-14007.
51. Zhang X, Niessner A, Nakajima T, Ma-Krupa W, Kopecky SL, et al. (2006) Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 98: 524-531.
52. Pistoia V, Cocco C, Airoldi I, (2009) Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol 27: 4809-4816.
53. Elkind MS, Rundek T, Sciacca RR, Ramas R, Chen HJ, et al. (2005) Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis 180: 181-187.
54. Bogdan C, Vodovotz Y, Paik J, Xie QW, Nathan C, (1994) Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J Leukoc Biol 55: 227-233.
55. Seder RA, Paul WE, (1994) Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12: 635-673.
56. Davenport P, Tipping PG, (2003) The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 163: 1117-1125.
57. Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF, (1994) Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 269: 27631-27634.
58. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, et al. (2001) Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89: 930-934.
59. Bursill CA, Channon KM, Greaves DR, (2004) The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 15: 145-149.
60. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, et al. (2006) Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 103: 3781-3786.
61. Hansson GK, Libby P, (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
62. Niedzielska I, Cierpka S, Interferon gamma in the etiology of atherosclerosis and periodontitis. Thromb Res 126: 324-327.
63. Maldonado RA, Soriano MA, Perdomo LC, Sigrist K, Irvine DJ, et al. (2009) Control of T helper cell differentiation through cytokine receptor inclusion in the immunological synapse. J Exp Med 206: 877-892.
64. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH, (2004) A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 431: 527-532.
65. Stolle K, Weitkamp B, Rauterberg J, Lorkowski S, Cullen P, (2004) Laser microdissection-based analysis of mRNA expression in human coronary arteries with intimal thickening. J Histochem Cytochem 52: 1511-1518.
66. Helle KB, (1990) Chromogranins: Universal proteins in secretory organelles from paramecium to man. Neurochemistry international 17: 165-175.
67. Corti A, Chromogranin A, and the tumor microenvironment Cellular and molecular neurobiology 30: 1163-1170.
68. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, et al. (2006) Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American heart journal 152:927: e921-926.
69. Nguyen YK, (1994) Granulocyte colony stimulating factor. The Journal of the Florida Medical Association 81: 467-469.
70. Sugiyama Y, Yagita Y, Oyama N, Terasaki Y, Omura-Matsuoka E, et al. Granulocyte colony-stimulating factor enhances arteriogenesis and ameliorates cerebral damage in a mouse model of ischemic stroke. Stroke; a journal of cerebral circulation 42: 770-775.
71. Gjerstorff MF, Besir H, Larsen MR, Ditzel HJ, Expression, purification and characterization of the cancer-germline antigen GAGE12I: a candidate for cancer immunotherapy. Protein expression and purification 73: 217-222.
72. Kular RK, Yehiely F, Kotlo KU, Cilensek ZM, Bedi R, et al. (2009) GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res 29: 645-655.
73. Marshall AJ, Du Q, Draves KE, Shikishima Y, HayGlass KT, et al. (2002) FDC-SP, a novel secreted protein expressed by follicular dendritic cells. J Immunol 169: 2381-2389.
74. Gjerstorff MF, Ditzel HJ, (2008) An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens 71: 187-192.
75. Xiao S, McLean J, Robertson J, (2006) Neuronal intermediate filaments and ALS: a new look at an old question. Biochim Biophys Acta 1762: 1001-1012.
76. Tedder TF, Klejman G, Schlossman SF, Saito H, (1989) Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol 142: 2560-2568.
77. Fong KY, (2002) Immunotherapy in autoimmune diseases. Annals of the Academy of Medicine, Singapore 31: 702-706.
78. Czuczman MS, Gregory SA, The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia & lymphoma 51: 983-994.
79. Weigert J, Neumeier M, Schaffler A, Fleck M, Scholmerich J, et al. (2005) The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett 579: 5565-5570.
80. Mansson B, Wenglen C, Morgelin M, Saxne T, Heinegard D, (2001) Association of chondroadherin with collagen type II. J Biol Chem 276: 32883-32888.
81. Mikelis C, Koutsioumpa M, Papadimitriou E, (2007) Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer. Recent patents on anti-cancer drug discovery 2: 175-186.